P637: TIME-LIMITED TREATMENT WITH ACALABRUTINIB PLUS OBINUTUZUMAB IN TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: EARLY RESULTS OF AN ONGOING PHASE 2 TRIAL

ABSTRACT:

SUBMITTER: Burger J 

PROVIDER: S-EPMC10428860 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature